Key Launches and Product Approvals are Expected to Drive the Global Pseudomonas Aeruginosa Pneumonia Drug Market

 The global pseudomonas aeruginosa pneumonia drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in June 2019, Merck & Co has received the approval of the US Food and Drug Administration (FDA)  for the use of Zerbaxa. The Zerbaxa is used to treat adult patients ( 18 years and older) with hospital-acquired bacterial infection pneumonia and ventilator-associated pneumonia which is caused by the susceptible gram-negative microorganisms. The company further stated that efficacy was assessed based on all-cause mortality at day 28 and significant signs of improvement occurred after 7 to 14 days at the end of the treatment. 

Browse the full report description “Global Pseudomonas Aeruginosa Pneumonia Drug Market Size, Share & Trends Report by Type (Aerucin, EV-035, MEDI-3902, and Others) and by Application (Hospital, Clinic and Others) Forecast (2022-2028)“at https://www.omrglobal.com/industry-reports/pseudomonas-aeruginosa-pneumonia-drug-market

Moreover, in 2019, Teva Pharmaceuticals has launched a Tobramycin inhalation solution. This solution is packaged in plastic containers called ampules. The medicine is used to treat lung infections in patients with cystic fibrosis. Furthermore, in June  2020, Merck & Co received  US Food and Drug Administration (FDA) approval for the use of Recarbrio. Recarbrio is used to treat adult patients ( 18years and older) with hospital-acquired bacterial infection pneumonia and ventilator-associated pneumonia. Moreover, recarbrio was previously approved by FDA to treat patients with urinary tract infections who possess no alternative treatments. According to FDA, the safety and efficacy were evaluated in clinical trials of 535 hospitalized adults with VABP. Thus, the application was designated as Qualified Infectious Disease Program (QIDP) by the FDA.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Application

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Aridis Pharmaceuticals LLC, Johnson & Johnson Services Inc., Medlmmune LLC (Astrazeneca),  Pfizer Inc., and more among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Pseudomonas Aeruginosa Pneumonia Drug Market Report Segment

By Type

• Aerucin
• EV-035
• MEDI-3902
• Others 

By Application

• Hospitals
• Clinics
• Others

Global Pseudomonas Aeruginosa Pneumonia Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa